These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6480812)

  • 1. Transitory increment in urinary free 19-nor-deoxycorticosterone after diuretic-induced renin stimulation.
    Griffing GT; Wilson TE; Melby JC
    J Clin Endocrinol Metab; 1984 Nov; 59(5):931-5. PubMed ID: 6480812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary free 19-nor-deoxycorticosterone and deoxycorticosterone in human hypertension.
    Gomez-Sanchez CE; Holland OB; Upcavage R
    J Clin Endocrinol Metab; 1985 Feb; 60(2):234-8. PubMed ID: 3880766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 19-nor-deoxycorticosterone excretion in primary aldosteronism and low renin hypertension.
    Griffing GT; Dale SL; Holbrook MM; Melby JC
    J Clin Endocrinol Metab; 1983 Feb; 56(2):218-21. PubMed ID: 6337172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoassay for urinary free 19-nor-deoxycorticosterone: effects of adrenocorticotropin and sodium depletion.
    Gomez-Sanchez CE; Gomez-Sanchez EP; Upcavage RJ
    Endocrinology; 1983 Jun; 112(6):2046-9. PubMed ID: 6303757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Converting-enzyme inhibitor administration lowers urinary free 19-nor-deoxycorticosterone levels.
    Griffing GT; Wilson TE; Melby JC
    Hypertension; 1985; 7(2):178-81. PubMed ID: 2984116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of urinary free 19-nor-deoxycorticosterone and its relation to systemic arterial blood pressure in normotensive and hypertensive subjects.
    Griffing GT; Dale SL; Holbrook MM; Melby JC
    J Clin Endocrinol Metab; 1983 Jan; 56(1):99-103. PubMed ID: 6292258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and urinary 19-nor-deoxycorticosterone in 17 alpha-hydroxylase deficiency syndrome.
    Griffing GT; Wilson TE; Holbrook MM; Dale SL; Jackson TK; Ullrich I; Melby JC
    J Clin Endocrinol Metab; 1984 Nov; 59(5):1011-5. PubMed ID: 6332824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unconjugated and conjugated urinary 19-nor-deoxycorticosterone glucosiduronate. Elevated levels in essential hypertension.
    Griffing GT; Wilson TE; Melby JC
    Hypertension; 1985; 7(3 Pt 2):I12-7. PubMed ID: 3873413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low renin essential hypertension: failure to demonstrate excess 11-deoxycorticosterone production.
    Tan SY; Mulrow PJ
    J Clin Endocrinol Metab; 1979 Nov; 49(5):790-3. PubMed ID: 489719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated urinary 19-Nor-deoxycorticosterone glucuronide in Cushing's syndrome.
    Ehlers ME; Griffing GT; Wilson TE; Melby JC
    J Clin Endocrinol Metab; 1987 May; 64(5):926-30. PubMed ID: 3558730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses of the renal prostanoids to a short-term depletion of sodium or potassium in healthy women.
    Agnoli GC; Borgatti R; Cacciari M; Garutti C; Ikonomu E; Lenzi P; Marinelli M; Stipo L
    Boll Soc Ital Biol Sper; 1996; 72(3-4):109-16. PubMed ID: 8771911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulation of plasma 18-hydroxy 11-deoxycorticosterone in man.
    Williams GH; Braley LM; Underwood RH
    J Clin Invest; 1976 Jul; 58(1):221-9. PubMed ID: 180059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 18-hydroxy-11-deoxycorticosterone and 16 alpha, 18-dihydroxy-11-deoxycorticosterone in hypertension.
    Melby JC; Dale SL
    Mayo Clin Proc; 1977 May; 52(5):317-22. PubMed ID: 870774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An adrenal cyst associated with 19-nor-deoxycorticosterone excess and low renin hypertension.
    Griffing GT; Chobainian AV; Egdahl R; Ehlers ME; Melby JC
    Clin Exp Hypertens A; 1989; 11(2):317-21. PubMed ID: 2650931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary 19-nor-deoxycorticosterone and deoxycorticosterone in hypertensive disease of pregnancy.
    Shah DM; Gomez-Sanchez CE; Knuppel RA; Vaughn WK
    Am J Perinatol; 1987 Apr; 4(2):102-5. PubMed ID: 3566877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 19-Nordeoxycorticosterone excretion in male and female inbred salt-sensitive (S/JR) and salt-resistant (R/JR) Dahl rats.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Endocrinology; 1988 Mar; 122(3):1110-3. PubMed ID: 3342746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of the zona fasciculata and glomerulosa to plasma 11-deoxycorticosterone levels in man.
    Tan SY; Mulrow PJ
    J Clin Endocrinol Metab; 1975 Jul; 41(1):126-30. PubMed ID: 168227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic 19-nor-deoxycorticosterone excretion after adrenal enucleation is associated with altered adrenal mitochondrial cytochrome P450 11 beta-, 18-, and 19-hydroxylase activities.
    Griffing GT; Wilson TE; Alexander EA; Bengele HH; Perrone RD; Melby JC
    Endocrinology; 1987 Aug; 121(2):645-9. PubMed ID: 3496214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of salt-wasting disorders of adrenal and renal origin.
    Rösler A
    J Clin Endocrinol Metab; 1984 Oct; 59(4):689-700. PubMed ID: 6384251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further studies of the mineralocorticoid activity of 19-oxo-deoxycorticosterone.
    Kenyon CJ; Saccoccio NA; Morris DJ
    Endocrinology; 1984 Aug; 115(2):535-7. PubMed ID: 6745168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.